TDG Gold Provides 2025 Exploration Outlook & Update on the Aurora1 West Target
Exploration scheduled to commence in June 2025 with IP followed by Drilling
TDG Gold Corp. (TSXV:TDG) (the "Company" or "TDG") is pleased to provide an update on its 2025 exploration plans for the AuRORA1 West ("AuWEST") target within the Company's expansive and 100%-owned Greater Shasta-Newberry ("GSN") Project in the Toodoggone District of British Columbia.
The AuWest Target - An Overview
Occurring immediately adjacent to the eastern boundary of the Company's GSN Project, the 2024 Freeport-McMoRan - AMARC Resources Ltd. ("Freeport-Amarc") AuRORA1 discovery represents an unusually high-grade, gold-copper-silver ("Au-Cu-Ag") discovery in the Toodoggone District (see TDG news release Jan 17, 2025). TDG's AuWEST target is the potential westward extension of AuRORA1.
The AuRORA1 mineralization was drill delineated to within ~40 metres ("m") of TDG's eastern property boundary. Freeport-Amarc's drillhole JP24073 (Amarc news release dated Jan 20, 2025a) intersected 1.40 g/t Au, 0.34 % Cu, 2.81 g/t Ag over 131.0 m, including a higher-grade subinterval averaging 1.62 g/t Au, 0.37 % Cu, 2.94 g/t Ag over 95.0 m. This intercept begins at 102 m below surface and was drilled westerly, towards the TDG-Freeport-Amarc property boundary, and was terminated at a downhole depth of 399 m, adjacent to the eastern TDG-Freeport-Amarc property boundary (Figure 1 & Figure 2). TDG has not independently verified the Freeport-Amarc drilling data, and mineralization hosted on adjacent properties is not necessarily indicative of mineralization hosted on TDG's property.
"The Toodoggone District is seeing a renaissance as a result of the AuRORA1 discovery. We are in the early days of determining the implications of this discovery, not only for how the Toodoggone District is viewed moving forward, but also for providing TDG and its stakeholders exposure to a priority drill target within metres of high-grade mineralization1," said Fletcher Morgan, CEO of TDG Gold Corp. Mr. Morgan continued by stating: "Utilizing the publicly available data, TDG's technical team has generated interpretative models of the AuRORA1 mineralization to assist with targeting of potential extensions. These models also utilized TDG's geological, geochemical and geophysical data with the objective of establishing a mineralization signature that can be used for targeting across TDG's extensive land holdings. With one of the largest land holding in the District, a substantial amount of historical exploration data and funding, TDG is well-positioned to undertake a broader exploration program across its holdings, in addition to drilling AuWEST, right on the boundary with AuRORA1."
Induced Polarization Geophysical Survey
Despite AuRORA's1 near surface nature, the mineralized zone does not appear to display a clear surficial geochemical signature and seems to be essentially a 'blind' target. However, based on Amarc's news release dated Jan 17, 2025b, an Induced Polarization ("IP") chargeability anomaly in excess of 20 millivolts per voltb ("mV/V") appears to correlate with the AuRORA1 discovery.
Based on these results over and around the AuRORA 1 discovery, TDG plans to undertake an IP survey over the southern portion of its GSN Property to evaluate potential extensions of the IP anomaly onto TDG's ground to assist with drill targeting.
Figure 1 - Location Map of TDG Targets.
Figure 2 - AuRORA1 Zone cross section looking due north. Envelope width 25 metres. Refer to Figure 1 for section location.
Airborne ZTEM Data Interpretation
Z-Tipper Electromagnetic ("ZTEM") geophysical technique is a deep penetrating airborne method that measures relative resistivity contrasts in the sub-surface. This method has the ability to discern relative resistivity contrasts that occur between differing rock types at depth - potentially including intrusive porphyry bodies.
TDG possesses the data from an historical and spatially extensive, detailed ZTEM and magnetic airborne dataset that covers the broader GSN-AuRORA1 area. This ZTEM data displays a geophysical response that substantiates geometry of the Amarc-reported mineralization at AuRORA1, and appears to support TDG's interpretation of a potential extension of AuRORA1 through to the AuWEST target. Similar responses in ZTEM geophysical data are also evident at TDG's Shasta South and Newberry targets, providing support for these areas as exploration targets.
Magnetic Responses and Implications for TDG
Porphyry systems commonly have anomalous magnetic patterns associated with Cu-Au mineralization. The presence (or absence via hydrothermal destruction of magnetite) of magnetite can cause distinct magnetic anomalies in geophysical surveys and may be an indicator of a porphyry centre situated vertically below or proximal to an anomalous magnetic response.
The AuRORA1 discovery displays, based on Amarc's news release dated Jan 17, 2025b, a magnetic signature due to the reported abundance of magnetite occurring in the rocks that appears to be spatially associated with the Au-Cu mineralization. TDG's Shasta South and Newberry targets are also host to discrete magnetic features with an amplitude and geometry comparable to that observed at AuRORA1, supporting the prioritization as exploration targets.
Soil Survey - AuRORA1 Pathfinders
At the same time as the IP survey, and to be completed prior to drill targeting, TDG will undertake an extensive soil survey covering the GSN area, subject to field conditions. Although a few generations of historical soil surveys exist in this area and outline strong geochemical anomalies immediately west of AuRORA 1, the data sets are often limited in extent and/or did not analyse for a complete package of trace element pathfinders typically associated with porphyry-style mineralization.
In addition to the obvious porphyry pathfinder elements of Cu, Au and Ag, a full suite of trace element geochemistry will be analysed and used to assist with drill target selection. The 2025 IP and soil surveys will help prioritize targets in this underexplored area prior to initial drill testing.
Geology
TDG has the benefit of a number of geological mapping programs over the GSN area, but many of these were undertaken with a focus on understanding regional geology and/or epithermal Au-Ag opportunities. Very little mapping has focused on the often subtle, but unique features of porphyry Cu-Au systems. TDG has retained the services of a team of experienced porphyry geologists who will be mapping and sampling the GSN area in parallel with the geophysical and geochemical programs with the objective of better understanding the geology of this area prior to drilling.
2025 Drilling
Following completion of IP and soil geochemistry over priority areas immediately west of AuRORA1, TDG plans to mobilize a helicopter portable drill rig in early July 2025 with an initial focus on testing the AuWEST target. Results-driven targeting may justify additional rigs to test other areas defined by the planned 2025 geophysical, geological and geochemistry surveys.
Qualified Person
The technical content of this news release has been reviewed and approved by Steven Kramar, MSc., P.Geo., Vice President, Exploration for TDG., a qualified person as defined by National Instrument 43-101.
Notes
1Adjacent Properties: The Company has no interest in, or rights to, any of the adjacent properties mentioned, and exploration results on adjacent properties are not necessarily indicative of mineralization on the Company's properties. Any references to exploration results on adjacent properties are provided for information only and do not imply any certainty of achieving similar results on the Company's properties.
2Mineral Resource Estimate (MRE): All scientific and technical information relating to the TDG's Shasta Project pertaining to the Mineral Resource Estimate ("Shasta MRE") contained in this news release is derived from TDG News Release Jan 08, 2025 and is available on the TDG Website. An updated technical report for the 2024 MRE will be filed within 45 days of January 8th, 2025, on Sedar+ https://www.sedarplus.ca/.
aAmarc Resources LTD, Amarc Announces Additional Drill Results from the AuRORA Copper-Gold-Silver Deposit Discovery in Collaboration with Freeport at the Joy District, British Columbia, Jan 20, 2025, Amarc Website (here).
bAmarc Resources LTD, Amarc Announces New High Grade "AuRORA" Copper-Gold-Silver Deposit Discovery in Collaboration with Freeport at the Joy District, British Columbia, Jan 17, 2025, Amarc Website (here).
About TDG Gold Corp.
TDG is a major mineral tenure holder in the historical Toodoggone Production Corridor of north-central British Columbia, Canada, with over 32,000 hectares of brownfield and greenfield exploration opportunities under direct ownership. TDG's most advanced projects are the former producing, high-grade gold-silver Shasta and Baker mines, which produced intermittently between 1981-2012, and the historical high-grade gold Mets developed prospect, all of which are road accessible, and combined have over 65,000 m of historical drilling. These projects have been advanced through compilation of historical data, new geological mapping, geochemical and geophysical surveys and, at Shasta, 13,250 m of modern HQ drill testing of the known mineralization occurrences and their potential extensions. In May 2023, TDG published an updated Mineral Resource Estimate for Shasta (news release May 01, 2023) which remains open at depth and along strike. In January 2023, TDG defined a larger exploration target area adjacent to Shasta ('Greater Shasta-Newberry'; news release Jan 25, 2023) which abuts Amarc-Freeport's AuRORA discovery. In Fall 2023, TDG published the first modern drill results from the Mets mining lease (news releases Sep 07, 2023, Sep 11, 2023 and Nov 28, 2023). In early 2024, TDG identified new copper-gold target areas over an expanded footprint covering ~53 sq.km known as the 'Baker Complex' (news release Feb 28, 2024).
ON BEHALF OF THE BOARD
Fletcher Morgan
Chief Executive Officer
For further information contact:
TDG Gold Corp.
Telephone: +1.604.536.2711
Email: info@tdggold.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as "expand", "represent", "apparent", "display", "potential", "demonstrate", "impressive", "appear", "corroborate", "anomaly", "realize", "considerable", "obvious", "establish", "extrapolate", "extensive", "leverage", "correlate", "discern", "common", "abundance", "steadfast", "similar", "evident", "support", "display", due to", "discrete", "compare", "expansive", "underexplored", "define", "plan", and variations of these words as well as other similar words or statements that certain events or conditions "could", "may", "would" or "will" occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the uncertainty that any mineralization encountered on adjacent properties continues on to TDG tenure; the uncertainty that geological and/or geophysical and/or geochemical anomalies and/or any trends, interpretations, or conclusions based on adjacent properties have relevance to TDG's tenure; whether geophysical anomalies and targets located on TDG's properties represent epithermal and/or porphyry-style mineralization and, if so, whether such mineralization has economic potential; the actual results of current and planned exploration activities; the actual timing of current and planned exploration activities; the interpretation that the Greater Shasta-Newberry Target Area represents a larger mineralized system encompassing several target zones and the potential that such zones may represent additional mineralized target zones; changes in project parameters as plans to continue to be refined; accidents, labour disputes and other risks of the mining industry; the availability of sufficient funding on terms acceptable to the company to complete the planned work programs; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
SOURCE: TDG Gold Corp.
This story was originally published May 7, 2025 at 7:02 AM.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
NEUPATH HEALTH REPORTS SECOND QUARTER 2025 RESULTS
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2025 and information regarding the Company's investor webinar on Thursday, August 21, 2025. All figures are in Canadian dollars, unless otherwise noted. 'Our core business continues to perform well, supported by improved capacity utilization, strong early demand for Arthrosamid ®, and the continued focus by the entire NeuPath team on the patient journey and outcomes,' said Joe Walewicz, NeuPath's Chief Executive Officer. 'Adjusting for the benefit of a one-time retroactive payment, we delivered strong growth and improved cash flows that reflect the work of our team to mitigate cost pressures and optimize our clinic footprint. We expect further investments in the second half of the year to enhance our clinic network, and with the addition of Stephen Lemieux as President, we are accelerating our focus on strategic opportunities. We believe we are well-positioned for continued growth in the second half of 2025 and beyond.' Financial and Operational Highlights Record total revenue of $23.6 million and $43.0 million for the three and six months ended June 30, 2025, up 25% and 18% year-over-year; Adjusted EBITDA was $2.2 million and $3.5 million for the three and six months ended June 30, 2025, up 69% and 61% year-over-year; For the six months ended June 30, 2025, capacity utilization improved to 79%, up from 75% for the six months ended June 30, 2024; As at June 30, 2025, the Company had $3.8 million in cash and cash equivalents and interest-bearing long-term debt of $6.5 million; and Following the launch of Arthrosamid (2.5% iPAAG) in March, there was substantial uptake in Q2, with continued patient interest in this novel procedure. Q2 2025 Financial Results Total Revenue Total revenue is comprised of clinic revenue and non-clinic revenue. Total revenue was $23.6 million and $43.0 million for the three and six months ended June 30, 2025 compared to $18.9 million and $36.4 million for the three and six months ended June 30, 2024. Clinic Revenue Clinic revenue is generated through the provision of medical services to patients. Clinic revenue was $22.2 million and $40.3 million for the three and six months ended June 30, 2025 compared to $17.3 million and $33.4 million for the three and six months ended June 30, 2024. The increase in clinic revenue for the three and six months ended June 30, 2025 was primarily due to positive adjustments to physician reimbursement rates including a material one-time payment in the quarter related to prior period physician reimbursements and stronger revenues from fluoroscopy. Capacity utilization was 84% and 79% for the three and six months ended June 30, 2025 compared to 77% and 75% in the three and six months ended June 30, 2024. The improvement in capacity utilization was primarily driven by stronger revenues and the continued optimization of clinic space. Non-clinic Revenue Non-clinic revenue was $1.4 million and $2.7 million for the three and six months ended June 30, 2025 compared to $1.6 million and $2.9 million for the three and six months ended June 30, 2024. Non-clinic revenue is earned from physician staffing allocation services where the Company provides physicians for provincial and federal correctional institutions across Canada, and from contract research services provided to pharmaceutical companies and clinical research organizations. This revenue fluctuates depending on the need for physicians in certain institutions and the timing and enrolment of clinical studies that the Company is working on. Gross margin % was 19.8% and 19.4% for the three and six months ended June 30, 2025 compared to 20.0% and 19.3% for the three and six months ended June 30, 2024. The increase in gross margin during the current three and six-month periods was primarily driven by positive adjustments to physician reimbursement rates including a material one-time payment in the quarter related to prior period physician reimbursements and stronger revenues from fluoroscopy (see Non-IFRS Financial Measures - Gross Margin and Gross Margin %). Adjusted EBITDA was $2.2 million and $3.5 million for the three and six months ended June 30, 2025 compared to $1.3 million and $2.2 million for the three and six months ended June 30, 2024. Liquidity and Capital Resources As at June 30, 2025, the Company's net debt was $2.7 million, an improvement from $3.1 million as at June 30, 2024. The Company's net debt as at June 30, 2025 consisted of $3.8 million of cash and cash equivalents and long-term debt of $6.5 million compared to $2.9 million of cash and cash equivalents and long-term debt of $6.0 million as at June 30, 2024. For more information see Note 5, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2025, and Note 6, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2024. Non-IFRS Financial and Other Measures The Company discloses non-IFRS measures (such as EBITDA, Adjusted EBITDA, and gross margin) and non-IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by International Financial Reporting Standards ('IFRS'). The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS. EBITDA and Adjusted EBITDA EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines Adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, executive long-term performance and retention bonus, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction costs, impairment charges, gain on sale of building, government loans forgiveness, finance income and loss or gain on sale of property, plant and equipment. Management believes EBITDA and Adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company's ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes. The following table provides a reconciliation of net and comprehensive income to EBITDA and Adjusted EBITDA: Gross Margin and Gross Margin % Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services ('COMS'). Gross margin % is calculated as gross margin divided by total revenue. The following table provides a reconciliation of total revenue to gross margin: Three months ended June 30 Six months ended June 30 2025 2024 2025 2024 $ $ $ $ Clinic revenue 22,209 17,266 40,255 33,434 Non-clinic revenue 1,421 1,614 2,710 2,932 Total revenue 23,630 18,880 42,965 36,366 Cost of medical services 18,951 15,096 34,646 29,349 Gross margin (1) 4,679 3,784 8,319 7,017 Gross margin % (1) 19.8% 20.0% 19.4% 19.3% Expand (1) Gross margin and gross margin % are non-IFRS measures. Please refer to Non-IFRS Financial Measures above. Expand For further details on the results, please refer to NeuPath's Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2025, which are available on the Company's website ( and under the Company's profile on SEDAR+ ( Notice of Investor Webinar Event: Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH) Presentation Date & Time: Thursday, August 21, 2025 at 10:00 AM ET / 7:00 AM PT Webcast Registration Link: About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Forward-Looking Statements This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2025 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR + under the Company's profile at Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Business Wire
4 hours ago
- Business Wire
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2025 Financial Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2025 financial results on Wednesday, August 21, 2025, before markets open. A conference call and webcast to discuss the financial results will be held on Wednesday, August 21, 2025, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: To listen and participate via the conference call, please dial: North American Toll-Free: 1-800-549-8228 Local (Toronto): 289-819-1520 Local (New York): 646-564-2877 Conference ID: 77702 Participants will be able to ask questions of Company management during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast. A recording of the call will be available on under News & Events on the Investors tab. Copies of Covalon's financial statements and MD&A can be obtained on SEDAR PLUS at and under SEDAR Filings on the Investors tab of Covalon's website. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
Business Upturn
14 hours ago
- Business Upturn
Flow Capital Announces Q2 2025 Financial Results
By GlobeNewswire Published on August 14, 2025, 03:35 IST Loan Interest Revenue up 54% and Recurring Free Cash Flow up 212% year over year TORONTO, ON, Aug. 13, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW), a leading provider of flexible growth capital and alternative debt solutions, announces its unaudited financial and operating results for the three- and six-month periods ended June 30, 2025. Performance Highlights Three Months Ended June 30, 2025, Compared to Three Months Ended June 30, 2024: 54% increase in Loan Interest Revenue to $3.2 million from $2.1 million 212% increase in recurring free cash flow to $884,129 from $283,036 216% increase in recurring free cash flow per share to $0.0290 from $0.0092 39% increase in total investments value to $72.2 million from $52.0 million $16.3 million in new investments compared to $9.3 million Six Months Ended June 30, 2025, Compared to Six Months Ended June 30, 2024 49% increase in Loan Interest Revenue to $6.1 million from $4.1 million 148% increase in recurring free cash flow to $1.7 million from $698,887 152% increase in recurring free cash flow per share to $0.0567 from $0.0224 39% increase in total investments value to $72.2 million from $52.0 million $19.5 million in new investments compared to $16.0 million 'Q2 2025 represented the 8th consecutive quarter of loan interest revenue growth. More importantly, we are growing our revenue while consistently generating positive free cash flow, with a total of $884,129 for the quarter compared to only $283,036 a year ago. We believe our continued strong growth indicates the strength of our business model and management's ability to execute on it.' said Alex Baluta, CEO of Flow Capital. Detailed Financial Results are available on our website at or on Results of Operations Click here to view image (1) Recurring Free Cash Flow is an internally defined, non-IFRS measure calculated as loan interest revenue less loan amortization income, one-time payments, salaries, professional fees, office and general administrative expenses, and financing expenses. See the section 'Use of Non-IFRS Financial Measures'. Conference Call Details Flow Capital will host a conference call to discuss these results at 9:30 a.m. Eastern Time, on Thursday August 14, 2025. Participants should call +1 800-717-1738 or +1 289-514-5100 and ask an operator for the Flow Capital Earnings Call, Conference ID 29927. Please dial in 10 minutes prior to the call to secure a line. A replay will be available shortly after the call. To access the replay, please dial +1 888-660-6264 or +1 289-819-1325 and enter passcode 29927#. The replay recording will be available until 11:59 p.m. ET, August 28, 2025. An audio recording of the conference call will be also available on the investors' page of Flow Capital's website at About Flow Capital Flow Capital Corp. is a publicly listed provider of flexible growth and alternative capital solutions dedicated to supporting market-leading high-growth companies. Since its inception in 2018, the company has provided financing to businesses in the US, the UK, and Canada, helping them achieve accelerated growth while minimizing dilution and retaining founder control. Flow Capital focuses on revenue-generating, VC-backed, and founder-owned companies seeking growth capital to drive their continued expansion. Learn more at For further information, please contact: Flow Capital Corp. Alex BalutaChief Executive Officer [email protected] 47 Colborne St, Suite 303, Toronto, Ontario M5E 1P8 Non-IFRS Financial Measures This press release includes references to the non-IFRS financial measure 'Recurring Free Cash Flow.' This financial measure is employed by the Company to measure its operating and economic performance, to assist in business decision-making, and to provide key performance information to senior management. The Company believes that, in addition to conventional measures prepared in accordance with IFRS, certain investors and analysts use this information to evaluate the company's operating and financial performance. This financial measure is not defined under IFRS, nor does it replace or supersede any standardized measure under IFRS. Other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure. Reconciliations of non-IFRS measures to the nearest IFRS measure can be found in this press release under 'Reconciliation of Non-IFRS Measures.' Reconciliation of Non-IFRS Measures The table below reconciles Recurring Free Cash Flow for the periods indicated. Recurring Free Cash Flow is an internally defined, non-IFRS measure calculated as loan interest and royalty income less loan amortization income, one-time payments, salaries, professional fees, office and general administrative expenses, and financing expenses. Please click here to view image Forward-Looking Information and Statements Certain statements herein may be 'forward-looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Flow or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Flow assumes no obligation, except as required by law, to update any forward-looking statements to reflect new events or circumstances. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
